Anti-angiogenic therapy using the multi-tyrosine kinase inhibitor Regorafenib enhances tumor progression in a transgenic mouse model of ß-cell carcinogenesis.
Journal Information
Full Title: Br J Cancer
Abbreviation: Br J Cancer
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Competing interests The authors declare no competing interests."
Funding Disclosure
Evidence found in paper:
"Funding This work was supported in part by grants from the Deutsche Forschungsgemeinschaft DFG (Mi710/8-1 and GRK2751/1 to PM). Open Access funding enabled and organized by Projekt DEAL."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025